当前位置： SCI文献检索 > Clinical Genitourinary Cancer期刊下所有文献 > Expression of microRNAs in the urine of patients with bladder cancer.

Expression of microRNAs in the urine of patients with bladder cancer.

Abstract：

UNLABELLED:We quantified the urine sediment and supernatant levels of microRNA (miRNA) targets related to epithelial-mesenchymal transition in 51 patients with bladder cancer and in 24 controls. We found that patients with bladder cancer had depressed levels of the miR-200 family, miR-192, and miR-155 in urinary sediment. The urinary level of these miRNAs may be developed as noninvasive markers for bladder cancer. BACKGROUND:MicroRNAs (miRNA) have been implicated to play an important role in the pathogenesis of a variety of cancers. We studied the levels of miRNAs related to epithelial-mesenchymal transition (EMT) in the urine of patients with bladder cancer. METHOD:The expression of the miR-200 family, miR-205, miR-192, miR-155, and miR-146a in the urine sediment and supernatant of 51 patients with bladder cancer and in 24 controls was determined by real-time quantitative polymerase chain reaction. RESULTS:Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant. The expression of the miR-200 family, miR-205, and miR-192 in the urine sediment significantly correlated with urinary expression of EMT markers, including zinc finger E-box-binding homeobox 1, vimentin, transforming growth factor β1, and Ras homolog gene family, member A. Furthermore, the levels of miR-200c and miR-141 in the urine sediment became normalized after surgery. CONCLUSION:We found that the urinary miR-200 family, miR-155, miR-192, and miR-205 levels are depressed in patients with bladder cancer. The level of these miRNA targets in urine has the potential to be developed as noninvasive markers for bladder cancer.

journal_name

Clin Genitourin Cancer

journal_title

Clinical genitourinary cancer

authors

Wang G,Chan ES,Kwan BC,Li PK,Yip SK,Szeto CC,Ng CF

doi

10.1016/j.clgc.2012.01.001

subject

Has Abstract

pub_date

2012-06-01 00:00:00

pages

106-13

issue

2

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(12)00026-2

journal_volume

10

pub_type

杂志文章

相关文献

Clinical Genitourinary Cancer文献大全
  • Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.

    abstract：BACKGROUND:Cabozantinib showed efficacy and manageable toxicity in patients with metastatic renal cell carcinoma (mRCC). In this study we aimed to describe the safety and to collect evidence on the potential efficacy of cabozantinib in mRCC patients with brain metastases (BM) in a real-world experience. MATERIALS AND ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.05.002

    authors： Peverelli G,Raimondi A,Ratta R,Verzoni E,Bregni M,Cortesi E,Cartenì G,Fornarini G,Facchini G,Buti S,Galli L,Tucci M,Prisciandaro M,Procopio G

    更新日期：2019-08-01 00:00:00

  • Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer.

    abstract：INTRODUCTION:The objective of this study was to examine the overall survival (OS) in patients diagnosed with high-grade T1 non-muscle-invasive bladder cancer treated with early radical cystectomy versus local treatment of the primary tumor, defined as endoscopic management with or without intravesical chemotherapy or i...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2020.03.013

    authors： Tully KH,Roghmann F,Noldus J,Chen X,Häuser L,Kibel AS,Sonpavde GP,Mossanen M,Trinh QD

    更新日期：2020-12-01 00:00:00

  • Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells.

    abstract：INTRODUCTION:Circulating tumor cells (CTCs) have great potential as circulating biomarkers for solid malignancies. Currently available assays for CTC detection rely on epithelial markers with somewhat limited sensitivity and specificity. We found that the staining pattern of nucleolin, a common nucleolar protein in pro...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.12.004

    authors： Chalfin HJ,Verdone JE,van der Toom EE,Glavaris S,Gorin MA,Pienta KJ

    更新日期：2017-06-01 00:00:00

  • The value of peritoneal washing cytology during intra-abdominal surgery for female genital tract neoplasms.

    abstract：BACKGROUND:Peritoneal washing cytology is a technique performed during surgery for genital neoplasms to detect subclinical intraperitoneal metastases from these tumors. The aim of this study was to evaluate PWC utility in presumed benign and malignant female genital tract neoplasms by comparing the results of peritonea...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2013.11.010

    authors： Giordano G,Varotti E,Brigati F,Berretta R

    更新日期：2014-06-01 00:00:00

  • Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.

    abstract：BACKGROUND:Nonurothelial carcinoma (UC) malignancies have traditionally been considered to have a more aggressive clinical course, and little is known about their response to neoadjuvant therapy. We examined the effect of neoadjuvant chemotherapy (NAC) on a large population of patients with bladder cancer (BCa) with di...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2020.01.007

    authors： Bandini M,Pederzoli F,Madison R,Briganti A,Ross JS,Niegisch G,Yu EY,Bamias A,Agarwal N,Sridhar SS,Rosenberg JE,Bellmunt J,Pal SK,Galsky MD,Lucianò R,Gallina A,Salonia A,Montorsi F,Ali SM,Chung JH,Necchi A

    更新日期：2020-10-01 00:00:00

  • Gynecologic Organ Involvement During Radical Cystectomy for Bladder Cancer: Is It Time to Routinely Spare the Ovaries?

    abstract：PURPOSE:To determine a subset of women who could undergo ovary-sparing radical cystectomy (OSRC) for bladder cancer without compromising oncologic safety. PATIENTS AND METHODS:A retrospective review was performed of 164 consecutive women who underwent cystectomy at a single tertiary-care center from 1997 to 2018. Clin...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.10.009

    authors： Taylor BL,Matrai CE,Smith AL,Ayangbesan A,Xia L,Golombos DM,Mosquera JM,Nicolas J,Robinson BD,Scherr DS,Khani F

    更新日期：2019-02-01 00:00:00

  • Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.

    abstract：BACKGROUND:Everolimus is an approved agent for use after disease progression with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma. With recently published trials showing efficacy of nivolumab and cabozantinib in the second-line therapy...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.12.011

    authors： Patel SB,Stenehjem DD,Gill DM,Tantravahi SK,Agarwal AM,Hsu J,Vuong W,Pal SK,Agarwal N

    更新日期：2016-04-01 00:00:00

  • Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.

    abstract：OBJECTIVE:Second-line systemic therapy for advanced urothelial carcinoma (UC) has substantial unmet needs, and current agents show dismal activity. Second-line trials of metastatic UC have used response rate (RR) and median progression-free survival (PFS) as primary endpoints, which may not reflect durable benefits. A ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clgc.2013.09.002

    authors： Agarwal N,Bellmunt J,Maughan BL,Boucher KM,Choueiri TK,Qu AQ,Vogelzang NJ,Fougeray R,Niegisch G,Albers P,Wong YN,Ko YJ,Sridhar SS,Tantravahi SK,Galsky MD,Petrylak DP,Vaishampayan UN,Mehta AN,Beer TM,Sternberg CN,R

    更新日期：2014-04-01 00:00:00

  • Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.

    abstract：BACKGROUND:Level 1 evidence has demonstrated increased overall survival with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer. Usage remains low, however, in part because neoadjuvant chemotherapy will not be effective for every patient. To identify the patients most likely to...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2016.03.006

    authors： O'Donnell PH,Alanee S,Stratton KL,Garcia-Grossman IR,Cao H,Ostrovnaya I,Plimack ER,Manschreck C,Ganshert C,Smith ND,Steinberg GD,Vijai J,Offit K,Stadler WM,Bajorin DF

    更新日期：2016-12-01 00:00:00

  • Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.

    abstract：BACKGROUND:Results from large randomized controlled trials combining docetaxel, abiraterone, celecoxib, or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer have emerged. However, in our knowledge, few data are available in patients older than 70 years. Therefore, we undertook...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clgc.2019.05.001

    authors： Landre T,Guetz GD,Chouahnia K,Fossey-Diaz V,Taleb C,Culine S

    更新日期：2019-08-01 00:00:00

  • Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice.

    abstract：BACKGROUND:Non-muscle-invasive bladder cancer (NMIBC) can be treated using transurethral resection (TUR), but high incidence of intravesical recurrence remains a clinical challenge. Single immediate postoperative instillation of chemotherapy (IPIOC) is controversial for NMIBC patients with intermediate recurrence risk....

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.05.028

    authors： Murakami K,Hamada A,Teramoto Y,Matsumoto K,Kita Y,Saito R,Yamasaki T,Matsui Y,Inoue T,Ogawa O,Kobayashi T

    更新日期：2019-10-01 00:00:00

  • Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.

    abstract：:Epigenetic alterations, including methylation of key tumor suppressor genes, may play a role in the progression of prostate cancer to a castration-refractory state. Azacitidine, an agent approved for the treatment of myelodysplastic syndromes, appears to exert its antineoplastic effects partly by hypomethylating DNA t...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2007.n.036

    authors： Sonpavde G,Aparicio A,Guttierez I,Boehm KA,Hutson TE,Berry WR,Asmar L,von Hoff DD

    更新日期：2007-12-01 00:00:00

  • Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.

    abstract：INTRODUCTION:Oxidative stress has been found to be associated with the progression of prostate cancer (PCa); however, human studies which identify differential roles of each oxidation pathway in PCa progression are lacking. We aimed to identify which oxidative stress markers, specifically lipid and global oxidation and...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.09.014

    authors： Wu T,Kasper S,Wong RM,Bracken B

    更新日期：2020-04-01 00:00:00

  • Development of a Novel Prognostic Risk Score for Predicting Complications of Penectomy in the Surgical Management of Penile Cancer.

    abstract：INTRODUCTION:Penectomy for PC is useful in staging, disease prognosis, and treatment. Limited studies have evaluated its surgical complications. We sought to assess these complications and determine predictive models to create a novel risk score for penectomy complications. PATIENTS AND METHODS:A retrospective review ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.09.018

    authors： Velazquez N,Press B,Renson A,Wysock JS,Taneja S,Huang WC,Bjurlin MA

    更新日期：2019-02-01 00:00:00

  • Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.

    abstract：INTRODUCTION:There is scarce information regarding nivolumab treatment for metastatic renal cell carcinoma (mRCC) in patients with end-stage renal disease (ESRD). This study investigated the safety and efficacy of nivolumab in patients with mRCC and ESRD. MATERIALS AND METHODS:This 2-center retrospective study evaluat...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2019.04.004

    authors： Tachibana H,Kondo T,Ishihara H,Takagi T,Tanabe K

    更新日期：2019-08-01 00:00:00

  • Less satisfaction with information in patients with prostate cancer treated with surgery and salvage radiotherapy compared with patients treated with curative radiotherapy alone, despite similar health-related quality of life.

    abstract：BACKGROUND:This study examined patient perception of information received, satisfaction with that information, and its relation to health-related quality of life (HRQoL) and clinical and demographic variables before, during, and after radiotherapy (RT) for localized prostate cancer. PATIENTS AND METHODS:In 2010, 2 que...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2013.11.001

    authors： Majumder K,Brandberg Y,Johansson H,Nilsson S,Bergenmar M

    更新日期：2014-06-01 00:00:00

  • Eosinophilic rash secondary to temsirolimus.

    abstract：:We present a case of a 73-year-old female with metastatic renal cell carcinoma, clear cell histologic subtype, who developed pruritic rash after 2 weeks of 25 mg weekly infusions of temsirolimus. Rash was located on bilateral antecubital areas and posterior knees. Skin biopsy showed spongiotic dermatitis with eosinoph...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2009.n.019

    authors： Gandhi M,Kuzel T,Lacouture M

    更新日期：2009-08-01 00:00:00

  • Salvage Focal Cryotherapy Offers Similar Short-term Oncologic Control and Improved Urinary Function Compared With Salvage Whole Gland Cryotherapy for Radiation-resistant or Recurrent Prostate Cancer.

    abstract：BACKGROUND:We compared the short-term oncologic and functional outcomes of salvage focal cryotherapy (SFC) with those of salvage total cryotherapy (STC) for radiotherapy (RT)-persistent/recurrent prostate cancer. MATERIALS AND METHODS:We queried the Cryo On-Line Database registry for men who had undergone SFC and STC ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.11.009

    authors： Tan WP,ElShafei A,Aminsharifi A,Khalifa AO,Polascik TJ

    更新日期：2020-06-01 00:00:00

  • Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer.

    abstract：BACKGROUND:The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. PATIENTS AND METHODS:The data from 1532 consecutive patients who p...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.08.003

    authors： Moschini M,Karnes RJ,Suardi N,Bianchi M,Pellucchi F,Rocchini L,Damiano R,Serretta V,Salonia A,Montorsi F,Briganti A,Colombo R

    更新日期：2016-06-01 00:00:00

  • Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.

    abstract：INTRODUCTION:Clinical T1 (cT1) bladder cancer is associated with high rates of recurrence, upstaging, and progression. Guidelines recommend that these patients be treated with adjuvant intravesical Bacillus Calmette-Guérin immunotherapy (BCG) or upfront radical cystectomy (RC). We analyzed the National Cancer Database ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.01.007

    authors： Balakrishnan AS,Washington SL 3rd,Meng MV,Porten SP

    更新日期：2019-06-01 00:00:00

  • Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.

    abstract：BACKGROUND:Sunitinib malate, a targeted tyrosine kinase inhibitor, is standard of care for metastatic renal cell carcinoma (mRCC) and serves as the active comparator in several ongoing mRCC clinical trials. In this analysis we report benchmarks for clinical outcomes on the basis of International Metastatic Renal Cell C...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clgc.2018.04.005

    authors： Rini BI,Hutson TE,Figlin RA,Lechuga MJ,Valota O,Serfass L,Rosbrook B,Motzer RJ

    更新日期：2018-08-01 00:00:00

  • Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.

    abstract：BACKGROUND:Salvage treatment with either conventional-dose chemotherapy (CDCT) or high-dose chemotherapy with autologous stem cell transplantation (HDCT) offers curative potential for patients with relapsed or refractory germ cell tumor (GCT). However, the optimal initial salvage strategy remains controversial, and the...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.03.015

    authors： Narayan V,Gunnarsson O,Hwang WT,Squillante CM,Nathanson KL,Stadtmauer EA,Vaughn DJ

    更新日期：2016-12-01 00:00:00

  • Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.

    abstract：BACKGROUND:Renal dysfunction, poor performance status, and comorbidities may preclude frontline cisplatin-based chemotherapy in patients with advanced urothelial carcinoma (UC). The frequency of cisplatin-based chemotherapy administration in patients with advanced UC in community-based cancer centers is unknown. PATIE...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2011.11.005

    authors： Sonpavde G,Watson D,Tourtellott M,Cowey CL,Hellerstedt B,Hutson TE,Zhan F,Vogelzang NJ

    更新日期：2012-03-01 00:00:00

  • Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer.

    abstract：BACKGROUND:The objective of this study was to investigate whether the prior use of a novel androgen receptor-axis-targeted (ARAT) agent with or without subsequent taxane therapy could affect the efficacy of another ARAT agent in patients with metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND METHOD...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.07.005

    authors： Miyake H,Hara T,Ozono S,Fujisawa M

    更新日期：2017-04-01 00:00:00

  • Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.

    abstract：BACKGROUND:The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guérin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS:We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic c...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2019.10.021

    authors： D'Andrea D,Soria F,Abufaraj M,Pones M,Gontero P,Machado AT,Waksman R,Enikeev DV,Glybochko PV,Adonias SP,Nahas WC,Shariat SF,Chade DC

    更新日期：2020-02-01 00:00:00

  • Clinical Significance of Subclassification of Papillary Renal Cell Carcinoma: Comparison of Clinicopathologic Parameters and Oncologic Outcomes Between Papillary Histologic Subtypes 1 and 2 Using the Korean Renal Cell Carcinoma Database.

    abstract：INTRODUCTION:The aims of the present study were to compare the clinicopathologic characteristics between type 1 and type 2 papillary renal cell carcinoma (pRCC) and to evaluate the effect of the subclassification of pRCC on the oncologic outcomes after surgery. MATERIALS AND METHODS:The records of 274 patients with pR...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.07.020

    authors： Ha YS,Chung JW,Choi SH,Lee JN,Kim HT,Kim TH,Chung SK,Byun SS,Hwang EC,Kang SH,Hong SH,Chung J,Kwak C,Kim YJ,Kwon TG,Korean Renal Cell Carcinoma Study Group.

    更新日期：2017-04-01 00:00:00

  • What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening?

    abstract：BACKGROUND:In this study we aimed to determine the relationship between prostate-specific antigen (PSA)-related information obtained from the provider and PSA test uptake. With recent focus on patient-provider communication (PC) and the guidelines recommending against PSA tests for prostate cancer (PCa), PC regarding t...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.05.002

    authors： Haider MR,Qureshi ZP,Horner R,Friedman DB,Bennett C

    更新日期：2017-12-01 00:00:00

  • Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.

    abstract：INTRODUCTION:The objective of this study was to determine the effectiveness and safety of pazopanib in patients with intermediate-risk advanced/metastatic renal cell carcinoma in the PRINCIPAL study (NCT01649778). PATIENTS AND METHODS:Patients had clear-cell advanced/metastatic renal cell carcinoma and met intermediat...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.01.018

    authors： Procopio G,Bamias A,Schmidinger M,Hawkins R,Sánchez AR,Estevez SV,Srihari N,Kalofonos H,Bono P,Pisal CB,Hirschberg Y,Dezzani L,Ahmad Q,Rodriguez CS,Jonasch E

    更新日期：2019-06-01 00:00:00

  • Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma.

    abstract：INTRODUCTION:The introduction of active new agents, such as small molecules and checkpoint inhibitors, for the treatment of metastatic renal-cell cancer (mRCC) is associated with a relevant increase in costs, and it is therefore important to strike a balance between the costs of treatment and the added value represente...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.02.006

    authors： Giuliani J,Bonetti A

    更新日期：2018-06-01 00:00:00

  • Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.

    abstract：BACKGROUND:Carcinoma of the collecting ducts (CDC) of Bellini of the kidney is very rare but is among the most aggressive urologic entities. PATIENTS AND METHODS:Radical nephrectomy revealed CDC in stage pT3a pN2 M0 G3 in 2 male patients. Four courses of adjuvant chemotherapy with cisplatin and gemcitabine were given....

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2009.n.010

    authors： Staehler M,Schöppler G,Haseke N,Stadler T,Karl A,Siebels M,Ihrler S,Stief CG

    更新日期：2009-01-01 00:00:00